1. Scrip
  2. >>Business
  3. >>Earnings

Top 10 Drugs Q2 2024: Mounjaro Comes Roaring In

Skyrizi Also Makes Its Debut

 
• By Eleanor Malone

Keytruda and Ozempic held their positions as the number one and two best-selling drugs in the world in the second quarter, while Eli Lilly’s Mounjaro shot to sixth place.

One lion roaring up at another on rocks representing Mounjaro challenging Keytruda
Mounjaro looks set to challenge Keytruda eventually (Shutterstock)
Key Takeaways

Keytruda is expected to remain the top-selling drug through the coming years.

Biosimilar competition will soon drive Humira and Stelara out of the list.

Obesity, diabetes and cardiometabolic treatments are in the ascendant: Ozempic and Mounjaro are expected to consolidate their positions while Wegovy and Jardiance will join the list in 2025.

Eli Lilly’s Mounjaro (tirzepatide) became the world’s sixth-highest selling drug by quarterly sales in the second quarter of 2024

Keytruda (pembrolizumab), Merck & Co’s PD-1 targeted anticancer checkpoint inhibitor, remained the world’s best-selling drug by a long margin, a position it has held since the start of 2023 when COVID-19 products started to decline and AbbVie’s long-lived blockbuster Humira (adalimumab) finally lost US market exclusivity

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

More from Scrip Perspectives

Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends

 
• By Eleanor Malone

A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.

Tech, India Trends To Track: AI Agents, SaaS Disruption, Influencers, Insurance

 
• By Anju Ghangurde

Industry pundits talk about conversational AI for sales reps, the arrival of AI agents, a potential overhaul in the SaaS market for pharma enterprises and the tricky arena of influencer engagement in this instalment on key trends playing out on the tech front and in India. Expanding healthcare coverage is also improving the outlook for pharma in the country, they said.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 4: Artificial Intelligence and Data Science

 
• By Eleanor Malone

More than 50 executives across industry share their expectations for the impact of AI on the biopharma industry over the coming year. While target identification and drug discovery featured highly, the opportunities to engage with patients and healthcare providers more effectively and the need for suitable regulatory frameworks were also flagged up.